CM-24

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameCM-24
Drug Alias NameCM-24MK-6018CM-24 (MK-6018)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 1 inhibitors
TargetsCarcinoembryonic antigen related cell adhesion molecule 1
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsraelSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesFameWave Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[7] 
Inactive IndicationsUrinary Bladder NeoplasmsStomach Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A